Skip to main content

Table 1 Baseline hemodynamic characteristics of male and female patients carrying a BMPR2 mutation.

From: Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension

 

Male patients

Female patients

 

BMPR2 mutation non-carriers

n = 79

BMPR2 mutation carriers

n = 34

p

BMPR2 mutation non-carriers

n = 188

BMPR2 mutation carriers

n = 81

p

Age at diagnosis, yrs (mean ± SD)

47.8 ± 17.1

34.6 ± 16.8

< 0.0001

47.4 ± 15.8

36.4 ± 14.9

< 0.0001

NYHA

I-II

21 (26.6%)

6 (17.6%)

< 0.01

27 (14.4%)

11 (13.6%)

0.90

III

57 (72.2%)

21 (61.8%)

 

135 (71.8%)

55 (67.9%)

 

IV

1 (1.3%)

6 (17.6%)

 

20 (10.6%)

10 (12.3%)

 

Six-minute walk test distance, m

394 ± 96

377 ± 98

0.49

328 ± 119

343 ± 102

0.35

mPAP, mmHg

57 ± 14

63 ± 13

0.03

56 ± 14

62 ± 13

0.0007

RAP, mmHg

8 ± 5

8 ± 6

0.81

8 ± 5

8 ± 5

0.70

PCWP, mmHg

9 ± 3

8 ± 3

0.39

8 ± 3

8 ± 3

0.84

CI, L/min/m²

2.71 ± 0.83

2.17 ± 0.60

0.0003

2.45 ± 0.66

2.07 ± 0.62

< 0.0001

PVRi, mmHg/L/min/m²

19.6 ± 9.3

21.9 ± 13.5

0.29

20.5 ± 8.5

25.1 ± 11.1

0.0015

SvO 2, %

67 ± 8

59 ± 9

0.0015

61 ± 10

59 ± 10

0.09

Acute vasodilator responders, %

9 (11.4%)

1 (2.9%)

0.20

27 (14.4%)

1 (1.2%)

< 0.01

  1. BMPR2: bone morphogenetic protein receptor type 2, PAH: pulmonary arterial hypertension, NYHA = New York Heart Association, mPAP = mean pulmonary artery pressure, RAP = right atrial pressure, PCWP = pulmonary capillary wedge pressure, CI = cardiac index, PVRi = indexed pulmonary vascular resistance, SvO2 = mixed venous oxygen saturation, NO = nitric oxide.
  2. Results are expressed as mean ± SD